Nabriva Therapeutics PLC (FRA:NTY)
€ 0.665 0.065 (10.83%) Market Cap: 1.90 Mil Enterprise Value: 753,000.00 PE Ratio: 0 PB Ratio: 0 GF Score: 27/100

Nabriva Therapeutics PLC at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 11:20PM GMT
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Thank you, everybody. We're going to get moving here in the afternoon with our next company presenter. My name's Jason Gerberry. I'm the U.S. pharma analyst at Bank of America. I'm pleased to be introducing Nabriva and CEO, Ted Schroeder. So Ted, thanks for joining us at the conference.

Theodore R. Schroeder
Nabriva Therapeutics plc - CEO & Director

Hey, thanks for having us, Jason. Always appreciate it.

Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

So maybe I'm not sure if you want to provide any introductory remarks as it pertains to Nabriva and helping investors think about how Nabriva takes a differentiated approach to the anti-infective space.

Theodore R. Schroeder
Nabriva Therapeutics plc - CEO & Director

Yes, sure. Thanks. So I think what's different about Nabriva is that we have 2 compounds that are in front of the FDA. So

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot